Management of Antiangiogenic Therapy-Induced Hypertension

This publication has 67 references indexed in Scilit:

• Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
  Clinical Cancer Research, 2011
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
  JNCI: Journal of the National Cancer Institute, 2011
• Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
  Annals of Oncology, 2010
• The importance of endothelin-1 for vascular dysfunction in cardiovascular disease
  Cardiovascular Research, 2007
• Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab
  JNCI: Journal of the National Cancer Institute, 2007
• Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension
  American Journal of Kidney Diseases, 2007
• Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
  Annals of Oncology, 2007
• Hypertension as a predictive factor of Sunitinib activity
  Annals of Oncology, 2007
• Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis
  American Journal of Kidney Diseases, 2007
• Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
  New England Journal of Medicine, 2007